

RECEIVED
CENTRAL FAX CENTER

AUG 18 2005

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In re application of:	Lijun Wu, et al.		
Serial No.:	09/870,932	Group No.:	1647
Filed:	May 30, 2001	Examiner.:	Turner, Sharon L.
For:	ANTI-CCR5 ANTIBODIES AND KITS COMPRISING SAME		

Practitioner's Docket No. MPI96-027CP2RCEM (formerly 1855.1032-004)


PATENT

Certificate of Transmission under 37 CFR 1.8

1-571-273-8300

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on August 18, 2005



Signature

Ann Sherry

Typed or printed name of person signing Certificate

RECEIVED
OIP/EPAP
AUG 19 2005

Submitted herewith:

This Certificate of Transmission under 37 CFR 1.8	1 page
Power of Attorney and Correspondence Address	
Indication Form	1 page
Statement under 37 CFR 3.73(b)	1 page
Copy of Notice of Recordation of Assignment Document	
with copy of executed Assignment	8 pages
Change of Attorney Docket Number	1 page
Total	12 pages (including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
CENTRAL FAX CENTER

AUG 18 2005

PTO/SB/81 (04-05)

Approved for use through 11/30/2005. OMB 0851-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	09/870,932
Filing Date	May 30, 2001
First Named Inventor	Lijun Wu, et al.
Title	ANTI-CCR5 ANTIBODIES AND KITS.....
Art Unit	1647
Examiner Name	Turner, Sharon L.
Attorney Docket Number	MPI96-027CP2RCEM

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number:

30405

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

30405

☐ Firm or
Individual Name

Address

City

State

Zip

Country


Telephone

Email

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

SIGNATURE of Applicant or Assignee of Record

Signature		Date	August 18, 2005
Name	Jean M. Silver	Telephone	617-679-7336
Title and Company	Associate General Counsel		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☒ *Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/86 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Millennium Pharmaceuticals, Inc.Application No./Patent No.: 09/870,932 Filed/Issue Date: May 30, 2001Entitled: ANTI-CCR5 ANTIBODIES AND KITS COMPRISING SAMEMillennium Pharmaceuticals, Inc., a a Delaware corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012612, Frame 0743, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:


1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☒
- Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

Jean M. Silver
Printed or Typed Name

August 18, 2005

Date

617-679-7336


Telephone Number

Associate General Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



APRIL 23, 2002

PTAS

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

LISA M. TREANNIE, ESQ.

530 VIRGINIA ROAD, P.O. BOX 9133

CONCORD, MA 01742-9133

Chief Information Officer
Washington, DC 20231
www.uspto.gov

101998076A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/11/2002 ✓

REEL/FRAME: 012612/0743 ✓
NUMBER OF PAGES: 7


BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

✓ ASSIGNOR:
WU, LIJUN

DOC DATE: 01/18/2002

✓ ASSIGNOR:
MACKAY, CHARLES R.

DOC DATE: 01/18/2002

✓ ASSIGNEE:
MILLENNIUM PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE, MASSACHUSETTS 02139SERIAL NUMBER: 09870932
PATENT NUMBER:✓ FILING DATE: 05/30/2001
ISSUE DATE:MARCUS KIRK, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

08/18/05 15:20 FAX 617 551 8820

MILLENNIUM

AUG 18 2005

005

Docket No.: 1855.1032-004

ODMA\HODMA\MANAGE\284739.1

03-01-2002

REC



SHEET

101998076

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies)

1. Lijun Wu
2. Charles R. Mackay

2.11.02

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

Execution Date: 1) 1/18/02 and 2) 1/18/02

2. Name and address of receiving party(ies)

Name: Millennium Pharmaceuticals, Inc.

Internal Address:

Street Address: 75 Sidney Street

City: Cambridge State: MA ZIP: 02139

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s)
09/870,932

B. Patent No.(s)

FEB 11 2002

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Lisa M. Treannie, Esq.

Internal Address:

Hamilton, Brook, Smith & Reynolds, P.C.

Street Address: 530 Virginia Road, P.O. Box 9133

City: Concord State: MA ZIP: 01742-9133

6. Total number of applications and patents involved: [1]

7. Total Fee (37 C.F.R. 3.41)..... \$ 40.00

- ☒ Enclosed
☒ Authorized to charge any deficiencies or credit any overpayment to deposit account
☐ Authorized to be charged to deposit account

8. Deposit account number:

08-0380

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Lisa M. Treannie

Lisa M. Treannie
Signature (41,368)

1/21/02
Date

02/23/2002 DBYRHE

Name of Person Signing

01 FC:581

40.00 OP

Total number of pages including cover sheet, attachments, and document: [7]

BEST AVAILABLE COPY

Basket No. 1855.1032-004JointASSIGNMENT

WHEREAS, we, **Lijun Wu and Charles R. Mackay**, have invented a certain improvement in **Anti-CCR5 Antibodies and Methods of Use Therefor** described in an application for Letters Patent of the United States, the specification of which:

- ☐ is being executed on even date herewith and is about to be filed in the United States Patent Office;
- ☒ was filed on **May 30, 2001** as Application No. **09/870,932**;
- ☐ was patented under U.S. Patent No. ☐ on ☐.

WHEREAS, **Millennium Pharmaceuticals, Inc.** (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the **State of Delaware**, and having a usual place of business at **75 Sidney Street, Cambridge, Massachusetts 02139** desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, the entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention as described in said application, together with the entire right, title and interest in and to said application and such Letters Patent as may issue thereon; said invention, application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent. We hereby acknowledge that this assignment, being of the entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of substitution, reissue, divisional or continuation applications and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention or any application or patent directed thereto may be involved;

-2-

AND, we do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

IN TESTIMONY WHEREOF, we have hereunto set our hands and affixed our seals the date set forth below.

Inventor's Signature: _____


Lijun Wu


State/Commonwealth _____

of _____

County of _____

Then personally appeared before me the above-named **Lijun Wu** and acknowledged that she executed the foregoing instrument as her free act and deed this 18th day of January, 2002.

(SEAL)

 Notary Public
ANN SHERRY (print name)
My Commission expires 4/19/02

-3-

Inventor's Signature: _____

Charles R. Mackay

State/Commonwealth _____

of _____

County of _____

Then personally appeared before me the above-named **Charles R. Mackay** and acknowledged that he executed the foregoing instrument as his free act and deed this _____ day of _____, 200__.

(SEAL)

Notary Public

(print name)

My Commission expires ____/____/____

::ODMAMHODMAMManage;247516;1

18/01 02 FRI 13:21 FAX 61 2 9 8404

AIRP GARVAN INSTITUT
LEGAL DEPT.005
005

01/17/2002 21:12 FAX 617 374 0074

Bucket No. 1855.1032-004

Joint

ASSIGNMENT

WHEREAS, we, Lijun Wu and Charles R. Mackay, have invented a certain improvement in Anti-CCR5 Antibodies and Methods of Use Therefor described in an application for Letters Patent of the United States, the specification of which:

- ☐ is being executed on even date herewith and is about to be filed in the United States Patent Office;
- ☒ was filed on May 30, 2001 as Application No. 09/870,932;
- ☐ was patented under U.S. Patent No. [] on [].

WHEREAS, Millennium Pharmaceuticals, Inc. (hereinafter "ASSIGNEE"), a corporation organized and existing under the laws of the State of Delaware, and having a usual place of business at 75 Sidney Street, Cambridge, Massachusetts 02139 desires to acquire an interest therein in accordance with agreements duly entered into with us;

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of said agreements and of other good and valuable consideration, the receipt of which is hereby acknowledged, we have sold, assigned and transferred and by these presents do hereby sell, assign and transfer unto said ASSIGNEE, its successors, assigns and legal representatives, the entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to said invention as described in said application, together with the entire right, title and interest in and to said application and such Letters Patent as may issue thereon; said invention, application and Letters Patent to be held and enjoyed by said ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made; we hereby convey all rights arising under or pursuant to any and all international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for Letters Patent. We hereby acknowledge that this assignment, being of the entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein;

AND, we hereby further agree for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the aforesaid invention to said ASSIGNEE, its successors, assigns and legal representatives, but at its or their expense and charges, including the execution of applications for patents in foreign countries, and the execution of substitution, reissue, divisional or continuation applications and preliminary or other statements and the giving of testimony in any interference or other proceeding in which said invention or any application or patent directed thereto may be involved;

BEST AVAILABLE COPY

18/01 '02 FRI 13:21 FAX 61 2 8 8404
01/17/2002 21:13 FAX 617 374 0074

AIRP GARVAN INSTITUT
LEGAL DEPT.

006
006

-2-

AND, we do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

IN TESTIMONY WHEREOF, we have hereunto set our hands and affixed our seals the date set forth below.

Inventor's Signature: _____

Lijun Wu

State/Commonwealth _____

of _____

County of _____

Then personally appeared before me the above-named Lijun Wu and acknowledged that she executed the foregoing instrument as her free act and deed this _____ day of _____, 200__.

(SEAL)

Notary Public

(print name)

My Commission expires ____/____/____

18/01 '02 FRI 13:21 FAX 61 2 8 3 8404
01/17/2002 21:13 FAX 617 374 06..

AIRP GARVAN INSTITU
LEGAL DEPT.

007 007

-3-

Inventor's Signature: _____

Charles R. Mackay
Charles R. Mackay

18-Jan-2002

State/Commonwealth _____

of _____

County of _____

Then personally appeared before me the above-named Charles R. Mackay and acknowledged that he executed the foregoing instrument as his free act and deed this _____ day of _____, 200__.

(SEAL)

Notary Public

(print name)

My Commission expires ____/____/____

ODMAMHODMAMMange247516.1

Witnesses

Fabienne Mackay

18-01-2002

FABIENNE MACKAY

Alison Saunders

1811102

ALISON SAUNDERS

BEST AVAILABLE COPY

AUG 18 2005

012

Practitioner's Docket No. **MPI96-027CP2RCEM (formerly 1855.1032-004)** **PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Lijun Wu, et al.	Group No.:	1647
Serial No.:	09/870,932	Examiner.:	Turner, Sharon L.
Filed:	May 30, 2001		
For:	ANTI-CCR5 ANTIBODIES AND KITS COMPRISING SAME		


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CHANGE OF ATTORNEY DOCKET NUMBER

Dear Sir:

Please note that the Attorney Docket Number has been changed from **1855.1032-004** to **MPI96-027CP2RCEM**. Please reference **MPI96-027CP2RCEM** on all future correspondence.

Respectfully submitted,

August 18, 2005	MILLENNIUM PHARMACEUTICALS, INC. By  Kerri Pollard Schray Registration No. 47,066 40 Landsdowne Street Cambridge, MA 02139 Telephone -- (617) 551-3676 Facsimile -- (617) 551-8820
-----------------	---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office (1-571-273-8300).

Date: August 18, 2005

Signature

Ann Sherry

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 1)

BEST AVAILABLE COPY